MedEnrich | Página principal
Continue Watching
últimos vidéos
últimos vidéos
Brightcove Home Latest Listing
Cáncer de mama
Cáncer de mama
Brightcove Cards Listing
Cáncer de próstata
Brightcove Cards Listing
Mieloma múltiple
Mieloma múltiple
Brightcove Cards Listing
Popular en MedEnrich
Popular in Sin nombre
- Myelodysplastic Syndromes14m 13s
ASH 2022 Update on Myelodysplastic Syndromes
ASH 2022 - Update on Myelodysplastic Syndromeseln classification low risk mds low dose lenalidomide venetoclax viale -a tags: azacitidine - Cancer de prostata6m 59s
Managing Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC)
3 randomized clinical trials (SPRATAN- Apalutamide), (PROSPER -Enzalutamide) & (ARAMIS -Darolutamide) have shown consistent and almost similar benefit in Metastasis Free Survival in nmCRPCnmcrpc metastasis free survival spartan prosper & aramis clinical trial - Mieloma múltiple9m 20s
Integrating Pomalidomide Based Regimens in Multiple Myeloma
Integrating pomalidomide and dexamethasone in the treatment of relapsed or refractory multiple myeloma (RRMM) involves using them as a core regimen, often combined with other agents like bortezomib or monoclonal antibodies for enhanced efficacy.pomalidomide-dexamethasone rrmm management progression-free survival combination therapies - nasopharyngeal carcinoma44m 35s
Comprehensive Overview of Nasopharyngeal Carcinoma
Over the last few years treatment of Nasopharyngeal Carcinoma has evolved with minimally invasive surgery, advances in chemotherapy & immunotherapy.nasopharyngeal carcinoma immunotherapy - Cáncer de mama3m 56s
Duration of trastuzumab in patients with Her2 positive Metastatic Breast Cancer in prolonged remission
There are no randomized clinical trials addressing the continued use of Trastuzumab for Her2 positive MBC patients in prolonged remission and has become important and relevant clinical question.her2 positive mbc prolonged remission trastuzumab duration - Acute Myeloid Leukaemia12m 22s
EHA 2022 Updates : AML
EHA Updates AML : QuANTUM phase 3 study showed significant overall survival in adults having FLT3-ITD+ acute myeloid leukaemia with addition of quizartinib to standard induction and consolidation therapy alone.aml decitabine g-csf hypomethylating agents - Oncospecials14m 58s
Is TKI Monotherapy still relevant for advanced Renal Cell carcinoma
ICIs in combination with VEGF-targeted treatments have become standard of care in 1st line advanced RCC ,however there are certain group of patients wherein treatment with single agent TKI can still be considered optimal1st line rcc single agent tki - Oncospecials4m 33s
Case of Advanced Renal Cell Carcinoma patient with Rheumatoid Arthritis treated with single agent TKI
Learn about successful treatment of 72 year old Renal Cell Carcinoma Patient also suffering from Rheumatoid Arthritis treated with single agent TKIrenal cell carcinoma rheumatoid arthritis single agent tki - Cáncer de mama8m 50s
Immunotherapy of Early Breast Cancer
I-SPY2 clinical trial laid the foundation for Immunotherapy in Early Breast Cancer with Pembrolizumab added to Neoadjuvant Chemotherapy.keynote -522 immunotherapy early breast cancer - Oncology9m 34s
Case Based Learning in Cardio Oncology
Immunotherapy mediated cardiotoxicity like myocarditis & cardiovascular issues arising of cytokine release syndrome can become more common with increasing adoption of Immunotherapy in cancer treatment.car-t cell therapy cytokine release syndrome immunotherapy mediated myocarditis
- 1
ASH 2022 Update on Myelodysplastic Syndromes
- 2
Managing Nonmetastatic Castration-Resistant...
- 3
Integrating Pomalidomide Based Regimens in Multiple...
- 4
Comprehensive Overview of Nasopharyngeal Carcinoma
- 5
Duration of trastuzumab in patients with Her2...
- 6
EHA 2022 Updates : AML
- 7
Is TKI Monotherapy still relevant for advanced...
- 8
Case of Advanced Renal Cell Carcinoma patient with...
- 9
Immunotherapy of Early Breast Cancer
- 10
Case Based Learning in Cardio Oncology
Seminarios web anteriores
Seminarios web anteriores
Webinar Cards Listing
Artículos
Artículos
Medbytes Cards Listing
Iniciar sesión
Por favor inicie sesión para acceder a todo el contenido de MedEnrich
¿Es nuevo/a en MedEnrich? Regístrese ahora